This Phase 2 study aims to study to evaluate the efficacy and safety of study treatment in paticipants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
Age 50 - 80
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Age 60 - 85
Must have a study partner
The study addresses the need for an effective pharmacologic treatment for apathy in the dementias, including AD, FTD, LBD, VCI and mixed dementias.
We are conducting a study to better understand caregiving experiences in order to validate a new tool to help screen for caregiver burden related to swallowing difficulties. The information you provide will be combined with information from other participants to help us better understand caregiving experiences, especially related to swallowing difficulties.
The aim is to better understand the cognitive strengths and difficulties related to visuospatial skills among people with Mild Cognitive Impairment and/or early Alzheimer's Disease through cognitive tasks.